HELP (Helus Pharma) OCF Margin %: 0.00% (As of Dec. 2025)


HELP Helus Pharma Inc HELP
22 GF Score
Price $6.48
! 1 Warning Sign
View Full Analysis

What is Helus Pharma OCF Margin %?

Helus Pharma HELP +7.82% 22 OCF Margin % is 0.00% as of Dec. 2025. GuruFocus rates HELP with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 959 Biotechnology companies, Helus Pharma ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Helus Pharma's Cash Flow from Operations for the three months ended in Dec. 2025 was $-31.95 Mil. Helus Pharma's Revenue for the three months ended in Dec. 2025 was $0.00 Mil. Therefore, Helus Pharma's OCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Helus Pharma's current OCF Yield % is -26.58%.

The historical rank and industry rank for Helus Pharma's OCF Margin % or its related term are showing as below:


During the past 6 years, the highest OCF Margin % of Helus Pharma was -2202.91%. The lowest was -2202.91%. And the median was -2202.91%.

HELP's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Helus Pharma OCF Margin % Related Terms

Helus Pharma OCF Margin % Historical Data

* Premium members only.

The historical data trend for Helus Pharma's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helus Pharma OCF Margin % Chart

Helus Pharma Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
OCF Margin %
Get a 7-Day Free Trial -2,203.65 0.00 0.00 0.00 0.00

Helus Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HELP
22GF Score
Helus Pharma Inc HELP
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Helus Pharma OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Helus Pharma's OCF Margin for the fiscal year that ended in Mar. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Mar. 2025 )/Revenue (A: Mar. 2025 )
=-70.784/0
= %

Helus Pharma's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-31.947/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Helus Pharma (HELP) has a OCF Margin % of 0.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Helus Pharma and its competitors. According to the industry distribution chart, Helus Pharma ranks #999999 out of 959 companies in the Biotechnology industry.
Is Helus Pharma's OCF Margin % too high?
Helus Pharma's current OCF Margin % is 0.00%. Based on the distribution chart, Helus Pharma ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Helus Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Helus Pharma's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Helus Pharma ranks #999999 out of 959 companies for OCF Margin %. This places Helus Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Helus Pharma and its competitors. Helus Pharma's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helus Pharma stock overvalued right now?
Helus Pharma (HELP) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Helus Pharma's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Helus Pharma (HELP), the current OCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helus Pharma Business Description

Other Exchanges R7E:GermanyHELP:Canada
Address 100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
22GF Score

Get the complete analysis for HELP

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.48
Price